Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu] Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

Ahmadzadehfar, HojjatRahbar, KambizBaum, Richard P.Seifert, RobertKessel, KatharinaBogemann, MartinKulkarni, Harshad R.Zhang, JingjingGerke, CarolinFimmers, RolfKratochwil, ClemensRathke, HendrikIlhan, HarunMaffey-Steffan, JohannaSathekge, Mike MachabaKabasakal, LeventOsvaldo Garcia-Perez, FranciscoKairemo, KaleviMaharaj, MashaPaez, DianaVirgolini, Irene2021-02-152021-02-152021-01Ahmadzadehfar, H., Rahbar, K., Baum, R.P. et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial) European Journal of Nuclear Medicine and Molecular Imaging, 48, 113–122 (2021). https://doi.org/10.1007/s00259-020-04797-9.1619-7070 (print)1619-7089 (online)10.1007/s00259-020-04797-9http://hdl.handle.net/2263/78552This article is part of the Topical Collection on Oncology - GenitourinaryPlease read abstract in the article.en© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License.Radioligand therapyLu-PSMAChemotherapyCastration-resistant prostate cancer (CRPC)Metastatic CRPC (mCRPC)Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu] Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)Article